1. Home
  2. CTMX vs DOMO Comparison

CTMX vs DOMO Comparison

Compare CTMX & DOMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • DOMO
  • Stock Information
  • Founded
  • CTMX 2008
  • DOMO 2010
  • Country
  • CTMX United States
  • DOMO United States
  • Employees
  • CTMX N/A
  • DOMO N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • DOMO Computer Software: Prepackaged Software
  • Sector
  • CTMX Health Care
  • DOMO Technology
  • Exchange
  • CTMX Nasdaq
  • DOMO Nasdaq
  • Market Cap
  • CTMX 444.3M
  • DOMO 436.2M
  • IPO Year
  • CTMX 2015
  • DOMO 2018
  • Fundamental
  • Price
  • CTMX $2.48
  • DOMO $14.54
  • Analyst Decision
  • CTMX Strong Buy
  • DOMO Hold
  • Analyst Count
  • CTMX 2
  • DOMO 6
  • Target Price
  • CTMX $5.00
  • DOMO $12.17
  • AVG Volume (30 Days)
  • CTMX 2.7M
  • DOMO 701.6K
  • Earning Date
  • CTMX 08-07-2025
  • DOMO 08-28-2025
  • Dividend Yield
  • CTMX N/A
  • DOMO N/A
  • EPS Growth
  • CTMX 128.27
  • DOMO N/A
  • EPS
  • CTMX 0.49
  • DOMO N/A
  • Revenue
  • CTMX $147,557,000.00
  • DOMO $317,052,000.00
  • Revenue This Year
  • CTMX N/A
  • DOMO $1.71
  • Revenue Next Year
  • CTMX N/A
  • DOMO $2.43
  • P/E Ratio
  • CTMX $5.11
  • DOMO N/A
  • Revenue Growth
  • CTMX 23.81
  • DOMO N/A
  • 52 Week Low
  • CTMX $0.40
  • DOMO $6.01
  • 52 Week High
  • CTMX $3.10
  • DOMO $14.83
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 56.59
  • DOMO 66.83
  • Support Level
  • CTMX $2.15
  • DOMO $13.54
  • Resistance Level
  • CTMX $2.44
  • DOMO $14.53
  • Average True Range (ATR)
  • CTMX 0.24
  • DOMO 0.77
  • MACD
  • CTMX -0.05
  • DOMO -0.05
  • Stochastic Oscillator
  • CTMX 39.71
  • DOMO 90.18

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About DOMO Domo Inc. Class B

Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.

Share on Social Networks: